Clinical trials: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, open to volunteers
Systemic Lupus Erythematosus
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07233642
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Refractory Systemic Lupus Erythematosus
CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
The goal of this Phase I clinical trial is to evaluate the safety and tolerability of autologous CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy in adults with refractory systemic lupus erythematosus who have…
- Trial name
- NCT07432334
- Testing
- Autologous CD19-Targeted CAR-T Cells
- Where
- Vietnam
- Volunteers
- 8 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Systemic Lupus Erythematosus (SLE), Children
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab.
- Conditions
- Systemic Lupus Erythematosus (SLE), Children, Blinatumomab
- Trial name
- BRASLE (NCT06789107)
- Testing
- Blinatumomab 9ug
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Mao Jianhua
Systemic Lupus Erythematosus (SLE)
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
- Trial name
- NCT06945068
- Testing
- GB261
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Autoimmune Diseases
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
- Trial name
- SCAR02 (NCT06503224)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
System Lupus Erythematosus(SLE), Scleroderma
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the…
- Conditions
- System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG)
- Trial name
- NCT07470151
- Testing
- EVM18001 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erthematosus (SLE)
KN5501 Cell Injection for Refractory SLE(CLEAR)
The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE).
- Trial name
- CLEAR (NCT07358988)
- Testing
- KN5501 cell injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Ruitherapeutics Co., LTD
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Systemic Lupus Erythematosus
Alnuctamab for Refractory SLE (LATTE Study)
This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care…
- Trial name
- NCT07219563
- Testing
- Alnuctamab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Systemic Lupus Erythematosus, Lupus Nephritis
CHT105 for the Treatment of Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients.
- Trial name
- NCT07517536
- Testing
- anti-CD19/70 CAR T cells (CHT105)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
System Lupus Erythematosus(SLE)
Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YKST02 administered alone or in combination with YK012 in…
- Trial name
- NCT07512947
- Testing
- YKST02, YK012
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
SLE - Systemic Lupus Erythematosus
Allogeneic UCB-derived CAR-T for SLE
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults.
- Trial name
- NCT07274059
- Testing
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Chengdu Ucello Biotechnology Co., Ltd.
Systemic Lupus Erythematosus
SNC116 Therapy for Refractory Systemic Lupus Erythematosus
This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.
- Trial name
- NCT07748156
- Testing
- SNC116
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
- Trial name
- Cell therapy (NCT07490041)
- Testing
- KN5601
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus (SLE)
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with…
- Trial name
- NCT06010472
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changhai Hospital
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
MTS109 in Patients With Refractory Autoimmune Diseases
This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV)
- Trial name
- NCT07526350
- Testing
- MTS109
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital